Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

Shital Jibhe Article rating: 4.8

Overall volumes in futures & options currently stand at 2,92,22,973 contracts with a turnover of Rs.19,47,253.75 crore.

NFO Analysis: ITI Long Term Equity Fund
NFO Analysis: ITI Long Term Equity Fund

NFO Analysis: ITI Long Term Equity Fund

DSIJ Intelligence Article rating: 4.3

ITI Mutual Fund, the youngest fund house in India has launched ITI Long Term Equity fund as their third fund. Read on to know if you should subscribe to the NFO. 

Torrent Pharma: USFDA classifies Dahej facility as OAI
Torrent Pharma: USFDA classifies Dahej facility as OAI

Torrent Pharma: USFDA classifies Dahej facility as OAI

Pratik Shastri Article rating: 4.0

Ahmedabad-based pharma major, Torrent Pharma informed in a press release that USFDA has classified its Dahej facility as Official Action Initiated (OAI). Reacting to this, the stock dipped more than 2.50 per cent in Thursday's trade.

Market Close: Sensex breaks three day winning streak
Market Close: Sensex breaks three day winning streak

Market Close: Sensex breaks three day winning streak

DSIJ Intelligence Article rating: 3.3

The benchmark index dipped by 318 points on Thursday due to a closing session sell-off. Disappointing June quarter number and weak global cues weighed heavily against the Sensex's three-day rally during the week.

Mutual Fund Unlocked: CPSE ETF or ELSS Mutual Funds?
Mutual Fund Unlocked: CPSE ETF or ELSS Mutual Funds?

Mutual Fund Unlocked: CPSE ETF or ELSS Mutual Funds?

DSIJ Intelligence Article rating: 5.0

The recent budget announcement has given an added advantage to CPSE ETF in terms of taxation. So, should you consider investing in CPSE ETF instead of ELSS MFs? Let’s find out.

DFM Foods: Capacity addition boosts stock price
DFM Foods: Capacity addition boosts stock price

DFM Foods: Capacity addition boosts stock price

Pratik Shastri Article rating: 5.0

Delhi-headquartered snack food manufacturer, DFM Foods Limited reacted positively to the news of commissioning of its new production line in Noida.

Zydus Cadila completes enrolment for Saroglitazar Mg trials
Zydus Cadila completes enrolment for Saroglitazar Mg trials

Zydus Cadila completes enrolment for Saroglitazar Mg trials

Apurva Joshi Article rating: 4.2

Zydus Cadila has announced the completion of enrolment in Evidences II, Evidences III and Evidences V Phase 3 clinical trials of Saroglitazar Mg for treating Non-Alcoholic SteatoHepatitis (NASH).

RSS
First31783179318031813183318531863187Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR